ZYUS Life Sciences Announces Strategic Realignment to Prioritize Drug Development

About this update from Zyus Life Sciences Corporation

ZYUS Life Sciences Announces Strategic Realignment to Prioritize Drug Development /* Style Definitions */ span.prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.prnews_a { color:blue; } li.prnews_li { font-size:8pt; font-family:"Arial"; color:black; } p.prnews_p { font-size:0.62em; font-family:"Arial"; color:black; margin:0in; } .prntac{ TEXT-ALIGN: CENTER } Canada NewsWire Realignment includes the streamlining of operations and leadership structure to support the continued advancement of the Company's non-opioid pain therapeutic pipelineSASKATOON, SK, June 11, 2026 /CNW/ - ZYUS Life Sciences Corporation (the "Company") (TSXV: ZYUS), a clinical-stage life sciences company focused on the development and commercialization of novel non-opioid drug candidates for pain management, announces a strategic realignment of its corporate structure and leadership to strengthen its focus on the Company's core clinical development priorities. As part of this realignment, the Company will streamline operations by discontinuing its international business development activities. This decision is intended to reduce overhead costs and redirect resources toward the Company's drug development programs. The Company will also initiate a formal wind-down of its international legal entities.In connection with this strategic realignment, Keith Carpenter, Chief Strategy and Investment Officer, will step down from his role, effective June 11, 2026. A key member of the Company's executive team since 2018, Mr. Carpenter was an instrumental figure in many facets of the business over the past eight years. The Company thanks Mr. Carpenter for his contributions and dedication to ZYUS and wishes him well in his future endeavours."This realignment reflects our commitment to focusing resources on the areas that we believe will create the greatest value for patients and shareholders," said Brent Zettl, President and CEO of ZYUS. "By streamlining our operations, we are sharpening our focus on advancing our clinical-stage non-opioid drug development programs. We believe these actions will strengthen our operational efficiency and position the Company to deliver on its key clinical development objectives."About ZYUS Life Sciences CorporationZYUS (TSXV: ZYUS) is a life sciences company focused on the development and commercialization of novel cannabinoid-based pharmaceutical drug ...

View stock analysis, news, and events for Zyus Life Sciences Corporation